A dis­rup­tive bil­lion­aire with a yen for in­no­va­tion herds top re­searchers in­to a neoanti­gen can­cer coali­tion

One of the hottest fields in can­cer re­search that’s been breed­ing a slew of star­tups now has its own col­lab­o­ra­tive ef­fort un­der­way to help in­ves­ti­ga­tors march for­ward at a faster and more cer­tain pace.

The field is neoanti­gens, and the col­lab­o­ra­tive is the lat­est brain­child of The Park­er In­sti­tute for Can­cer Im­munother­a­py and its part­ners at the Can­cer Re­search In­sti­tute. Dubbed TES­LA, for Tu­mor neoanti­gEn Se­Lec­tion Al­liance (a twist on acronyms), the coali­tion will bring to­geth­er aca­d­e­m­ic and in­dus­try re­searchers who will use their own, in­di­vid­ual al­go­rithms to spot the unique neoanti­gens that ap­pear on in­di­vid­ual pa­tients’ can­cer cells in or­der to de­vel­op a per­son­al­ized cell ther­a­py specif­i­cal­ly for that in­di­vid­ual.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.